CEDARHURST, NY / ACCESSWIRE / September 27, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.
Cardinal Health, Inc. (CAH)
Investors Affected : March 2, 2015 - May 2, 2018
A class action has commenced on behalf of certain shareholders in Cardinal Health, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) following Cardinal's acquisition of Cordis, the RFID [radio-frequency identification] inventory tracking technology and advanced supply chain solutions that Defendants told investors the Company would to use to improve Cordis's performance were never implemented across Cordis; 2) Cordis's antiquated and ineffective global supply chain was causing operational and inventory problems at Cordis; 3) as a result, Cordis manufactured and accumulated excessive amounts of cardiovascular product inventories, which sat on the shelf and became unsellable and/or expired; 4) the Company materially overstated Cordis's inventory balances; 5) Cordis was not "performing well" and its integration was not "on track," "going incredibly well" or "largely on plan"; and 6) to correct Cordis's deficiencies, the Company would have to make substantial investments in Cordis's IT and supporting infrastructure, thereby incurring significant Selling, General and Administrative Expenses charges beyond the levels internally budgeted or projected by Cardinal and diminishing operating earnings.
Shareholders may find more information at https://kclasslaw.com/securities/cardinal-health-inc-loss-submission-form/?id=3745&from=1
Sarepta Therapeutics, Inc. (SRPT)
Investors Affected : September 6, 2017 - August 19, 2019
A class action has commenced on behalf of certain shareholders in Sarepta Therapeutics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen's accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://kclasslaw.com/securities/sarepta-therapeutics-inc-loss-submission-form/?id=3745&from=1
Tencent Music Entertainment Group (TME)
Investors Affected : December 12, 2018 - August 26, 2019
A class action has commenced on behalf of certain shareholders in Tencent Music Entertainment Group. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Tencent Music's exclusive licensing arrangements with major record labels were anticompetitive; (2) consequently, sublicensing such content from Tencent Music was unreasonably expensive, in violation of Chinese antimonopoly laws; (3) these anticompetitive efforts were reasonably likely to lead to regulatory scrutiny; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Shareholders may find more information at https://kclasslaw.com/securities/tencent-music-entertainment-group-loss-submission-form/?id=3745&from=1
Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967
SOURCE: Kuznicki Law PLLC
View source version on accesswire.com: